January 08, 2018
1 min read

NDA for Inveltys to treat postoperative inflammation, pain accepted

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has accepted a new drug application for Inveltys, a product candidate for the treatment of inflammation and pain in ocular surgery patients, according to a press release from Kala Pharmaceuticals.

If approved, Inveltys (KPI-121 1%) would be the first twice-daily ocular corticosteroid indicated for the treatment of postoperative ocular inflammation and pain, as all other drugs currently on the market are indicated for four times a day, the release said.

It uses Kala’s mucus-penetrating particle technology to enhance drug penetration and distribution in ocular tissues.

In two phase 3 clinical trials, Inveltys showed statistical significance for its primary efficacy endpoints of complete resolution of inflammation and pain at day 8 through day 15 compared with placebo, according to the release.

Inveltys has a Prescription Drug User Fee Act date of Aug. 24.